Featuring perspectives from Dr Naveen Pemmaraju, including the following topics:

• Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00)
• Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35)
• Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21)
• Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10)
• Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33)
• Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38)
• Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08)
• Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56)
• Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48)
• Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18)
• Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56)

CME information and select publications